BIOMUNEX is assembling cutting-edge national and international academic teams and experts to advance the development of therapeutics for the treatment of solid tumor cancers, such as head & neck, gastric, pancreatic, ovarian, and colon cancers. BIOMUNEX has already established a collaboration with INSERM, with the objective of identifying innovative treatments for pancreatic cancer. This collaborative project combines leading French academic groups from IRCM (Institut de Recherche en Cancérologie de Montpellier) and Tours University, and is funded by the French Agence Nationale de la Recherche (ANR).
BIOMUNEX continues to aggressively establish scientific collaborations with the leading research institutions in France, as well as elsewhere in Europe and the US, in order to leverage full potential of its unique BiXAb platform.
BIOMUNEX has established a collaboration with Professor M. Peipp at the Universitätsklinikum Schleswig-Holstein (University of Kiel, Germany) for testing BIOMUNEX’ lead candidates in solid tumor cancers and multiple myeloma models.
BIOMUNEX is also actively seeking to establish research collaborations with academic teams for discovery of novel cancer cell-targeting antigen pairs (immune checkpoints and tumor-associated antigens).